scholarly journals Onco-Surgical Management of Liver Metastases from Colorectal Cancer

10.5772/65223 ◽  
2017 ◽  
Author(s):  
Irinel Popescu ◽  
Sorin Tiberiu Alexandrescu
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Surgical Management

scholarly journals Surgical management and outcomes of colorectal cancer liver metastases

2010 ◽  
Vol 97 (7) ◽  
pp. 1110-1118 ◽  
Author(s):  
E. J. A. Morris ◽  
D. Forman ◽  
J. D. Thomas ◽  
P. Quirke ◽  
E. F. Taylor ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Surgical Management ◽  
Colorectal Cancer Liver Metastases

Chemotherapy-Associated Liver Injury: Impact on Surgical Management of Colorectal Cancer Liver Metastases

2010 ◽  
Vol 18 (1) ◽  
pp. 181-190 ◽  
Author(s):  
Peter J. Kneuertz ◽  
Shishir K. Maithel ◽  
Charles A. Staley ◽  
David A. Kooby
Keyword(s):  
Colorectal Cancer ◽  
Liver Injury ◽  
Liver Metastases ◽  
Surgical Management ◽  
Colorectal Cancer Liver Metastases

Surgical Management of Liver Metastases From Colorectal Cancer

2016 ◽  
Vol 12 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Mashaal Dhir ◽  
Aaron R. Sasson
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Liver Metastases ◽  
Surgical Resection ◽  
Surgical Management ◽  
Colorectal Liver Metastases ◽  
Multidisciplinary Approach ◽  
Treatment Options ◽  
Optimal Timing ◽  
Medical Oncologists

Surgical resection remains one of the major curative treatment options available to patients with colorectal liver metastases. Surgery and chemotherapy form the backbone of the treatment in patients with colorectal liver metastases. With more effective chemotherapy regimens being available, the optimal timing and sequencing of treatments are important. A multidisciplinary approach with the involvement of medical oncologists and surgical oncologists from the beginning is crucial. Identification of the clinical and molecular prognostic factors may help personalize the treatment approaches for these patients. This article provides an overview of the surgical management of colorectal liver metastases.

Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases

1978 ◽  
Vol 135 (1) ◽  
pp. 81-85 ◽  
Author(s):  
Harold J. Wanebo ◽  
Christopoulos Semoglou ◽  
Fadi Attiyeh ◽  
Maus J. Stearns
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Surgical Management ◽  
Synchronous Liver Metastases

Positron Emission Tomography Combined With Computed Tomography vs. No Positron Emission Tomography Combined With Computed Tomography for the Management of Patients With Resectable Colorectal Cancer Liver Metastases and Synchronous Extrahepatic Disease

2020 ◽  
pp. 000313482095483
Author(s):  
Pablo E. Serrano ◽  
Chu-Shu Gu ◽  
Carol-Anne Moulton ◽  
Steven Gallinger
Keyword(s):  
Colorectal Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Liver Metastases ◽  
Surgical Management ◽  
Emission Tomography ◽  
Colorectal Cancer Liver Metastases ◽  
Positron Emission ◽  
Pet Ct

Introduction Selected patients with colorectal cancer liver metastases (CRLM) and synchronous extrahepatic disease (EHD) are considered for surgery. Objectives To evaluate the change in surgical management and long-term survival (disease-free survival [DFS] and overall survival [OS]) for patients with CRLM and EHD who undergo positron emission tomography combined with computed tomography (PET-CT) vs no PET-CT. Methods Patients with CRLM were enrolled in a trial evaluating the effect of PET-CT (vs no PET-CT) on surgical management, DFS, and OS. This is a sub-study of the trial, including only patients with synchronous EHD. Cox proportional hazard models were used to calculate risks for recurrence and death. Survival were described by Kaplan-Meier method and compared with log-rank test. Results Of 25 patients with EHD (PET-CT arm: 14/270 (5%) and no PET-CT arm: 11/134 (8%)), PET-CT changed surgical management in 14%, all of which avoided liver resection due to more extensive disease. Complete metastasectomy was achieved in 36% (5/14) and 72% (8/11), respectively. Respectively, PET-CT vs no PET-CT had statistically similar median DFS, 5.6 months (95% confidence interval (CI) 3.6-18) vs 7.6 months (95% CI 2.9-15) and median OS, 42 months (95% CI 25-48) vs 29 months (95% CI 17-41). EHD was associated with worse DFS (hazard ratio HR = 1.89, 95% CI 1.41-2.52) and OS (HR = 2.47, 95% CI 1.6-3.83). Conclusions Preoperative PET-CT for the management of resectable CRLM did not improve long-term outcomes among patients who had synchronous EHD; however, it changed surgical management in a relatively significant proportion of patients.

Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: The long-term results of a randomized control trial.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 562-562
Author(s):  
Pablo Emilio Serrano Aybar ◽  
Chu-Shu Gu ◽  
Mohamed Husien ◽  
Diederick Jalink ◽  
Guillaume Martel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Surgical Management ◽  
Disease Recurrence ◽  
Long Term Results ◽  
Colorectal Cancer Liver Metastases ◽  
Pet Ct ◽  
Risks Factors

562 Background: The PETCAM randomized trial evaluated the effect of preoperative PET-CT (vs. no PET-CT) on surgical management in patients with colorectal cancer liver metastases. In this study, 8% of patients had a change in surgical management, including a higher proportion of major liver resections in the PET-CT arm. The current study compares the intervention groups for 5-year disease free (DFS) and overall survival (OS), and evaluated their long-term clinical course, i.e. sites of recurrence and management of disease recurrence. Methods: Recruitment to the trial occurred between 2005-2010, with last follow-up in 2013. Data on recurrence, management of recurrence and mortality from 2013-2017 was collected from patient’s charts. Recurrences according to site and management were described. Cox proportional Hazard Models were used to calculate the risk for recurrence and death. OS was calculated with Kaplan-Meir method and compared with log-rank test. Results: At 5 years, 157 of 404 (39%) patients were still alive and 19 patients were lost to follow-up. Median follow-up is 4.2 years. There were no differences in DFS (HR: 1.12, 95%CI: 0.88-1.42) or OS (HR: 0.97, 95%CI: 0.74-1.28) between groups. The median DFS for the 372 patients who had surgery was 17 months, 95%CI: 14.7-19.4. Risks factors for recurrence were: extrahepatic disease, liver tumour size, and nodal stage. The median OS for all patients was 50 months, 95%CI: 43.5-64.3. Risks factors for death also included age and prior use of chemotherapy. During the follow-up period, 287/404, 71% patients recurred (mostly liver and lung); 137 (48%) were treated solely with chemotherapy and 35% were treated with surgery with curative intent. Of these, the majority recurred (109/116, 94%). The median OS following first recurrence was 27.5 months, 95%CI: 23-30. Conclusions: PET-CT did not improve DFS or OS. Survival following liver resection is similar to previous reports, however most patients experience disease recurrence. A substantial proportion of patients who recur undergo surgery, however it is likely that they will recur again.

880 Concomitant Surgical Management of Synchronous Colorectal Cancer and Liver Metastases: A Comparison of Open and Laparoscopic Approaches

2015 ◽  
Vol 148 (4) ◽  
pp. S-1126
Author(s):  
Emre Gorgun ◽  
Pinar Yazici ◽  
Akin Onder ◽  
Sara Sound ◽  
Alexis K. Okoh ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Surgical Management ◽  
Synchronous Colorectal Cancer
Sign in / Sign up

Export Citation Format

Share Document